Pay in 4 interest-free payments of $6.20 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Efficacy and safety of GLP-1 medicines for type 2 diabetes and obesity Diabetes Care 2024;47(11):1873-1888 doi:10.2337/dci24-0003 (Review) Grasset E, Puel A, Charpentier J, et al
Pre-clinical studies showed that anti-atherogenic effect is independent of modulation of plasma lipid levels and depends on anti-inflammatory response
The whole processes need to be carried out on ice, and the enzyme activity should be determined on the same day, to avoid repeated freeze-thaw of the homogenate solution
For type 2 diabetes, NICE guidance recommends reviewing GLP-1 therapy at 6 months, continuing only if HbA1c has reduced by at least 11 mmol/mol (1.0%) and weight has decreased by at least 3% of initial body weight
